Amylin analogs

Cagrilintide is a long-acting amylin analog, a copy of amylin, the hormone your pancreas releases with insulin to signal fullness. In plain terms: it works on a different 'stop eating' pathway than the GLP-1 drugs, which is why it is often paired with semaglutide for bigger results.

Amycretin is a single molecule that combines GLP-1 and amylin activity. In plain terms: it packs two different 'stop eating' signals into one compound, with strong early weight-loss data. It is still experimental, in pill and injectable forms.

Pramlintide is a synthetic version of amylin, a hormone released with insulin. In plain terms: taken at meals alongside insulin in diabetes, it blunts the post-meal blood-sugar spike and reduces hunger. It is FDA-approved.

CagriSema is a fixed combination of cagrilintide (an amylin copy) and semaglutide (a GLP-1 copy) in one weekly shot. In plain terms: it hits two separate fullness pathways at once for bigger weight loss than either alone. It is still experimental.

Petrelintide is a long-acting amylin analog. In plain terms: it copies the pancreas's fullness hormone to reduce appetite, positioned as a gentler standalone weight-loss option. It is still experimental.

Eloralintide is an amylin receptor agonist from Eli Lilly. In plain terms: it copies the pancreas's fullness hormone for weight loss, designed to be easy to tolerate. It is still in trials.